An Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the AKT Inhibitor GSK690693 Given on Various Schedules in Subjects With Solid Tumors or Lymphoma
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the maximum tolerated dose of GSK690693 given weekly or twice weekly over 1 - 4 hours.
given weekly or twice weekly over 1 - 4 hours
GSK Clinical Trials, MD
United States: Food and Drug Administration
|GSK Investigational Site||Indianapolis, Indiana 46260|
|GSK Investigational Site||Royal Oak, Michigan 48073|